



Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The Nasdaq Stock Market Closing Bell

What:

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), a clinical stage bio-pharmaceutical company with a first-in-class monoclonal antibody, bertilimumab, for the treatment of auto-immune diseases, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Dr. **Daniel Teper, Chief Executive Officer** will ring the Closing Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, May 26, 2015 – 3:45 p.m. to 4:00 p.m. ET

Immune Pharmaceuticals Media Contact:

Anna Baran
(646) 937-1941
Anna.baran@immunepharma.com

Nasdaq MarketSite:

Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
<http://www.facebook.com/NASDAQ>.

For photos from ceremonies and events visit our Instagram Page:
<http://instagram.com/nasdaq>

For news tweets, please visit our Twitter page at:
<http://twitter.com/nasdaq>

For exciting viral content and ceremony photos visit Tumblr Page:
<http://nasdaq.tumblr.com/>

Webcast:

A webcast of the Nasdaq Closing Bell will be available at:

<https://new.livestream.com/nasdaq/live> or <http://www.nasdaq.com/about/marketsitetowervideo.aspx>

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to

http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Immune Pharmaceuticals Inc. (Nasdaq: IMNP):

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of AstraZeneca. Immune's pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for a Phase III clinical trial. AmiKet has received Orphan Drug Designation in the U.S. for Post-Herpetic Neuralgia.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately \$9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-